Enhancing PrEP Outcomes Among Kenyan Adolescent Girls and Young Women With a Novel Pharmacy-based PrEP Delivery Platform
Launched by UNIVERSITY OF WASHINGTON · Jul 15, 2022
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a new support system can help young women in Kenya start and continue using a preventive medication for HIV called PrEP. The study involves 20 pharmacies in Kisumu, where nurse-navigators will assist young women aged 14 to 24 who are seeking contraception. When these participants visit the pharmacy to get contraception, they will also be offered PrEP, either in the form of a daily pill or a different method. The researchers want to see if having a nurse to guide them helps these young women start taking PrEP and continue using it over a period of 10 months.
To be eligible for this study, participants must be female, aged between 14 and 24, and actively seeking contraception from the pharmacy. They should also be willing to undergo HIV testing, but they cannot already be taking PrEP. Throughout the study, participants can expect to receive support and information about PrEP, as well as regular follow-ups to track their progress. This trial is important because it aims to improve access to HIV prevention for young women in Kenya, ultimately helping to reduce the risk of HIV in this group.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female gender
- • Seeking contraception (EC, OCP, injectables, implants, and condoms) from the retail pharmacy site
- • Age between ≥14 and \<25 years old
- • Willingness to receive PrEP screening per national guidelines including HIV testing
- • Not currently taking PrEP
- • Able and willing to provide informed consent for participation
- Exclusion Criteria:
- • Male gender
- • Not seeking contraception (EC, OCP, injectables, implants, and condoms) from the retail pharmacy site
- • Age \<14 and \>24 years old
- • Not willing to receive PrEP screening per national guidelines including HIV testing
- • Currently taking PrEP
- • Not able and/or willing to provide informed consent for participation
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kisumu, , Kenya
Patients applied
Trial Officials
Jillian Pintye, PhD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials